ROTAPRO Rotational Atherectomy Systems
Boston Scientific Corp · Decision date Oct 21, 2026
What did the FDA approve?
The FDA record cited here describes a real-time process supplement for the ROTAPRO rotational atherectomy system, identified as P900056/S226 and dated 2026-10-21. The reported scope is a design change to a component of the Pneumatic Kit used with the ROTAPRO console. The supplement category is change in design, components, specifications or material, filed under product code MCX for a coronary atherectomy catheter.
The identifier ties the action to the existing P900056 approval and its applicant, Boston Scientific Corp. This is a supplement rather than a new approval of the whole system, and the record does not describe the component, the nature of the design change, or any safety or effectiveness determination. The source does not state that clinical data were reviewed, so the decision should not be read as independent proof of clinical benefit.
The record gives no detail on which Pneumatic Kit component changed or how. That information is absent.
FDA approval order statement
a design change to a component of the Pneumatic Kit for the ROTAPRO console
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 21, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P900056/S226
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- MCX
- Decision code
- APPR
- Decision date
- Oct 21, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: CATHETER, CORONARY, ATHERECTOMY.
- Applicant
- Boston Scientific Corp
- Product code
- MCX
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P900056. Subsequent supplements may change the device or its indications.
FDA decision timeline
P900056 · Original PMA
ROTABLATOR(R)
P900056/S221 · Related supplement
ROTABLATOR Rotational Atherectomy System
P900056/S222 · Related supplement
ROTAPRO Rotational Atherectomy System
P900056/S223 · Related supplement
ROTAPRO Rotational Atherectomy System
P900056/S224 · Related supplement
Rotablator; ROTAPRO Rotational Atherectomy Systems
P900056/S225 · Related supplement
ROTABLATOR Rotational Atherectomy System
P900056/S226 received
Application receipt date recorded by FDA.
P900056/S228 · Related supplement
ROTAPRO Rotational Atherectomy System
P900056/S229 · Related supplement
ROTAPRO Rotational Atherectomy System
P900056/S226 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P900056. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P900056
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ROTABLATOR(R)P900056 | Boston Scientific Corp | PMA approval | May 28, 1993 | FDA |
ROTABLATOR Rotational Atherectomy SystemP900056/S221 | Boston Scientific Corp | PMA supplement | Aug 14, 2025 | FDA |
ROTAPRO Rotational Atherectomy SystemP900056/S222 | Boston Scientific Corp | PMA supplement | Oct 27, 2025 | FDA |
ROTAPRO Rotational Atherectomy SystemP900056/S223 | Boston Scientific Corp | PMA supplement | Mar 5, 2026 | FDA |
| Boston Scientific Corp | PMA supplement | Apr 9, 2026 | FDA | |
ROTABLATOR Rotational Atherectomy SystemP900056/S225 | Boston Scientific Corp | PMA supplement | May 6, 2026 | FDA |
ROTAPRO Rotational Atherectomy SystemP900056/S228 | Boston Scientific Corp | PMA supplement | Oct 20, 2026 | FDA |
ROTAPRO Rotational Atherectomy SystemP900056/S229 | Boston Scientific Corp | PMA supplement | Oct 21, 2026 | FDA |
Explore the linked device profile
Other records with product code MCX
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cardiovascular Systems, Inc. | PMA supplement | Mar 10, 2026 | FDA | |
| Cardiovascular Systems, Inc. | PMA supplement | Feb 26, 2026 | FDA | |
| Cardiovascular Systems, Inc. | PMA supplement | Feb 18, 2026 | FDA | |
| Cardiovascular Systems, Inc. | PMA supplement | Jan 14, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- Two Scimed Pl., Maple Grove, MN, 55311
Sources and methodology
- Original FDA record: P900056/S226
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





